Latest News

Stay up to date with the latest stock market news from around the world. From breaking news written by our finance analysts to event-driven market news on a global scale.

NasdaqGM:ANTA
NasdaqGM:ANTAConsumer Finance

Antalpha Platform Holding (ANTA) Net Margin Surge Challenges Bearish Cash Flow Concerns

Antalpha Platform Holding (NasdaqGM:ANTA) has capped FY 2025 with fourth quarter revenue of about US$28.0 million and basic EPS of US$0.39, set against trailing 12 month revenue of roughly US$79.7 million and EPS of US$0.84 that are reported to be up very strongly year over year. The company has seen quarterly revenue move from around US$13.4 million in Q4 2024 to US$28.0 million in Q4 2025, while basic EPS over that same period shifted from US$0.09 to US$0.39, and trailing net profit margin...
NasdaqGS:CRWD
NasdaqGS:CRWDSoftware

CrowdStrike Targets EU Sovereign Cloud Demand With STACKIT Falcon Alliance

CrowdStrike Holdings (NasdaqGS:CRWD) is partnering with Schwarz Digits to bring its AI native Falcon cybersecurity platform to Europe’s STACKIT sovereign cloud. The collaboration focuses on supporting GDPR and regional data sovereignty requirements across European markets. By integrating Falcon into STACKIT, CrowdStrike is aiming at highly regulated industries that prioritize data residency and operational autonomy. CrowdStrike, known for its cloud delivered Falcon security platform, is...
NYSE:MOS
NYSE:MOSChemicals

Is Mosaic (MOS) Offering A Valuation Opportunity After Recent Share Price Swings?

If you are looking at Mosaic and wondering whether the current share price really reflects its underlying worth, this article will walk through what the numbers actually say. The stock recently closed at US$26.28, with returns of 8.7% over 1 year and 5.0% year to date, set against declines of 3.2% over the last week and 7.2% over the last month, so the market’s view on the company has not been one way. Recent news flow around Mosaic has largely focused on broader sector themes and company...
NasdaqCM:RGTI
NasdaqCM:RGTISemiconductor

Rigetti Computing (RGTI) Posts US$216 Million TTM Loss Reinforcing Profitability Concerns

Rigetti Computing (RGTI) has wrapped up FY 2025 with Q4 revenue of about US$1.9 million and a basic EPS loss of US$0.06, alongside a trailing twelve month EPS loss of US$0.70 and revenue of roughly US$7.1 million. Over the past six quarters, revenue has moved in a tight band between US$1.5 million and US$2.4 million, while quarterly basic EPS has swung from a profit of US$0.15 in early 2025 to losses as wide as US$0.68. This sets the scene for a story that is still heavily driven by top line...
NasdaqGS:PGNY
NasdaqGS:PGNYHealthcare

Progyny Adds INVO Fertility Clinic As Network Grows And Shares Lag

INVO Fertility has joined the Progyny (NasdaqGS:PGNY) provider network, adding its clinic to Progyny's fertility benefits platform. The partnership expands access to employer sponsored fertility care for patients in Wisconsin and nearby regions. This development broadens Progyny's provider footprint and increases potential touchpoints with covered employees seeking fertility treatment. Progyny runs a fertility benefits platform that connects employer sponsored health plans with a network of...
NYSE:MOH
NYSE:MOHHealthcare

Assessing Molina Healthcare’s (MOH) Valuation After Clustered Insider Buying By Top Executives

Recent insider filings at Molina Healthcare (MOH) show sizable share purchases by several top executives, a cluster of buying that often draws investor attention to management’s alignment with shareholders. See our latest analysis for Molina Healthcare. At a share price of US$147.71, Molina Healthcare’s recent 30‑day share price return of an 18.57% decline and year‑to‑date share price return of a 17.23% decline contrast with a much steeper 1‑year total shareholder return decline of 54.39%...
NasdaqGS:TEM
NasdaqGS:TEMLife Sciences

Tempus AI (TEM) Valuation Check As Merck Alliance Puts Its Precision Oncology Platform In Focus

Tempus AI (TEM) shares are back in focus after the company expanded its multi year collaboration with Merck, placing Tempus’ de identified data and Lens AI platform at the center of Merck’s precision oncology research. See our latest analysis for Tempus AI. Tempus AI’s latest collaboration news comes after a choppy few months for the stock, with a 1 day share price return of 3.43% lifting it to US$53.05. Over the last 90 days, the share price has declined 30.8%, which contrasts with an 8.58%...
NYSE:ACR
NYSE:ACRMortgage REITs

ACRES Commercial Realty (ACR) One Off Gain Raises Questions On Earnings Narratives

ACRES Commercial Realty (ACR) just closed out FY 2025 with fourth quarter total revenue of US$21.3 million and basic EPS of US$0.03 on a trailing twelve month basis, setting a tight spotlight on how its income stream is holding up. Over the past six reported quarters, total revenue has moved within a band of US$18.7 million to US$25.0 million per quarter, while quarterly basic EPS has ranged from a loss of US$0.80 to a gain of US$1.38, giving investors a wide spread of outcomes to parse. With...
CPSE:CARL B
CPSE:CARL BBeverage

Is It Time To Reassess Carlsberg (CPSE:CARL B) After Recent Share Price Weakness?

If you are wondering whether Carlsberg is fairly priced at its current level, this article will walk you through what the numbers say about its value and what that could mean for you. Carlsberg shares last closed at DKK 914.80, with returns of 7% decline over the past week, 3.6% over the past month, 10.8% year to date, 4.9% over one year, 2.3% decline over three years and 4.1% over five years. This gives a mixed picture of recent performance and risk perception. Recent news coverage around...
NasdaqGS:GEN
NasdaqGS:GENSoftware

What Gen Digital (GEN)'s AI-Powered Scam Protection Integrations Mean For Shareholders

In late February and early March 2026, Gen Digital expanded its cyber safety reach as MoneyLion launched LifeLock-powered identity protection for its members and Norton rolled out the Genie AI scam-protection assistant directly within ChatGPT, helping users assess emails, messages, images, and links in real time. Together, these launches highlight how Gen Digital is embedding its security and identity protection tools into partner platforms and everyday AI use, potentially deepening user...
NYSE:RBLX
NYSE:RBLXEntertainment

Are Roblox’s New AI Chat Tools Quietly Redefining Its Trust-Driven Growth Strategy (RBLX)?

In early March 2026, Roblox Corporation rolled out AI-driven real-time chat rephrasing and upgraded text filters to keep in-game conversations civil while more accurately detecting attempts to bypass its Community Standards across multiple languages and age-checked groups. This push to make communication smoother and safer highlights how central trust and moderation technology have become to Roblox’s effort to support large-scale user engagement and creator-driven experiences. Next, we'll...
NasdaqGS:VRTX
NasdaqGS:VRTXBiotechs

The Bull Case For Vertex Pharmaceuticals (VRTX) Could Change Following Opioid‑Sparing JOURNAVX Phase 4 Data - Learn Why

Vertex Pharmaceuticals recently reported Phase 4 data showing its non-opioid pain signal inhibitor JOURNAVX (suzetrigine) enabled effective, mostly opioid-free recovery for adults with moderate-to-severe acute pain after a range of plastic surgeries, with results being presented at the AAPM PainConnect 2026 meeting in Salt Lake City. The findings suggest JOURNAVX could become an important component of multimodal post-surgical pain care, potentially reducing dependence on opioids in aesthetic...
BIT:SRG
BIT:SRGGas Utilities

A Look At Snam (BIT:SRG) Valuation After Guidance Beat, €14b Plan And Higher Dividend

Snam (BIT:SRG) has just reported fiscal 2025 results that exceeded its own guidance, paired with a €14b investment plan through 2030 and a 4% dividend increase that keeps income focused investors watching closely. See our latest analysis for Snam. The latest €6.464 share price sits on top of an 11.53% 1 month share price return and a 14.45% year to date share price return. The 1 year total shareholder return of 54.01% and 5 year total shareholder return of 90.47% point to momentum that has...
SEHK:9926
SEHK:9926Biotechs

Akeso Data And INOVIO Deal Deepen Immunotherapy And Valuation Story

Akeso (SEHK:9926) reported long term survival data for cadonilimab in advanced cervical cancer, with benefits extending to patients who are PD L1 negative or resistant to prior therapies. The company also entered a collaboration with INOVIO to study a combination immunotherapy approach for glioblastoma. Akeso focuses on immuno oncology drugs, and cadonilimab is one of its key assets in gynecologic cancers. The fresh data around long term outcomes in advanced cervical cancer reinforces the...
NasdaqGS:RGNX
NasdaqGS:RGNXBiotechs

Regenxbio (RGNX) Q4 US$67 Million Loss Tests Bullish Revenue Growth Narrative

REGENXBIO (RGNX) closed out FY 2025 with Q4 revenue of US$30.3 million and a basic EPS loss of US$1.30, alongside a trailing twelve month EPS loss of US$3.76 on revenue of US$170.4 million. Over recent periods, the company has seen quarterly revenue range from US$21.4 million to US$89.0 million, while basic EPS has swung between a small profit of US$0.12 and losses of more than US$1.30 per share. This sets up a story that is heavily driven by how much investors are prepared to tolerate...
NYSE:RH
NYSE:RHSpecialty Retail

Is There Now An Opportunity In RH (RH) After The Recent Share Price Slump

For readers considering whether RH at around US$151.61 reflects an appropriate balance between potential upside and the risks involved, or whether the market has moved too far in the other direction, this article will help frame that question using a valuation lens. The stock has experienced sharp moves recently, with a 7 day return of an 18.8% decline, a 30 day return of a 24.0% decline, and a year to date return of a 21.6% decline. The 1 year return stands at a 46.0% decline and the 5 year...
TSE:8750
TSE:8750Insurance

Dai-Ichi Life Links Restricted Stock Awards To Long Term Shareholder Outcomes

Dai-ichi Life Holdings (TSE:8750) has granted new shares as restricted stock compensation to executives and related entities. The awards are tied to long term performance, aiming to align management incentives more closely with shareholder interests. This move comes as corporate governance practices across Japan's financial sector receive increased attention. For investors watching Dai-ichi Life Holdings at a share price of ¥1,523.5, the new restricted stock plan adds an extra layer to the...
TSX:ARE
TSX:AREConstruction

Aecon Group (TSX:ARE) Valuation After Earnings Strength Guidance Record Backlog And Arctic Radar Contract News

Aecon Group (TSX:ARE) has provided investors with several new updates, including fourth quarter results, 2026 revenue guidance connected to a record backlog, a modest dividend increase, and details on its involvement in Canada’s Arctic Over-the-Horizon Radar project. See our latest analysis for Aecon Group. These updates land after a strong run in the shares, with a 90 day share price return of 26.02% and a one year total shareholder return of 108.10%. This suggests momentum has been building...
TSX:CSU
TSX:CSUSoftware

Constellation Software (TSX:CSU) Valuation After Sabre Governance Deal And Poison Pill Termination

Constellation Software (TSX:CSU) is back in focus after Sabre Corporation agreed to add Damian McKay, head of its Vela Software division, to Sabre's board and terminated a previously adopted poison pill. See our latest analysis for Constellation Software. The Sabre agreement and poison pill reversal come as Constellation Software’s CA$2,796.99 share price has logged a 22.20% 1 month share price return, although the year to date share price return is a 13.65% decline and the 1 year total...
NasdaqGS:HSAI
NasdaqGS:HSAIAuto Components

A Look At Hesai Group (HSAI) Valuation As Governance And Capital Measures Are Approved

Hesai Group (HSAI) drew fresh attention after shareholders approved wide ranging governance and capital measures, including new articles of association, redesignated Class B shares and expanded authority for directors to issue and repurchase stock. See our latest analysis for Hesai Group. The governance and capital moves come after a sharp pullback, with a 1 day share price return of a 6.35% decline and a 7 day share price return of a 12.84% decline, even though the 90 day share price return...
NYSE:SPGI
NYSE:SPGICapital Markets

Is It Too Late To Consider Buying S&P Global (SPGI) After Recent Share Price Weakness?

If you are wondering whether S&P Global's current share price still offers value, you are not alone. This article will walk through what the market might be pricing in and what that could mean for you. The stock last closed at US$451.11, with returns of 3.1% over the past 7 days, a 3.7% decline over 30 days, a 12.0% decline year to date, an 11.6% decline over 1 year, and gains of 38.4% and 36.3% over 3 and 5 years respectively. Recent coverage around S&P Global has focused on its role as a...
NasdaqGS:HFWA
NasdaqGS:HFWABanks

Heritage Financial Partnership With Savant Raises Questions On Growth And Execution

Savant Wealth Management entered into a partnership with Heritage Financial, integrating Heritage's leadership and many employee-owners into Savant's ownership structure. The combination expands Savant's presence in Massachusetts and brings Heritage Financial, traded as NasdaqGS:HFWA, into closer alignment with Savant's operations. For you as an investor, this ties a regional wealth manager more closely to a larger advisory platform, while keeping Heritage Financial's client relationships...
NasdaqGS:TEAM
NasdaqGS:TEAMSoftware

Assessing Atlassian (NasdaqGS:TEAM) Valuation After AI Agent Launch And Investor Sentiment Rebound

Atlassian (TEAM) is back in focus after launching the open beta of AI agents in Jira and ramping up its Model Context Protocol efforts, a move that has coincided with a rebound in investor sentiment. See our latest analysis for Atlassian. The launch of AI agents in Jira and new MCP investments comes after a difficult period for the stock, with a 30-day share price return of a 21.42% decline and a 1-year total shareholder return showing a 67.08% loss. However, the recent 1-day gain of 7.42%...
NasdaqGS:CCRN
NasdaqGS:CCRNHealthcare

Cross Country Healthcare (CCRN) Quarterly Loss Of US$82.9 Million Tests Earnings Recovery Narrative

Cross Country Healthcare (CCRN) has capped FY 2025 with Q4 revenue of US$236.8 million and a basic EPS loss of US$2.56, alongside a Q4 net loss of US$82.9 million. On a trailing twelve month basis, revenue was US$1.1 billion with a basic EPS loss of US$2.93 and a net loss of US$94.9 million. Over recent quarters, revenue has moved from US$315.1 million and basic EPS of US$0.08 in Q3 2024 to US$236.8 million and basic EPS losses in each quarter of 2025. This has left investors weighing how the...